AR083722A1 - Formas cristalinas de inhibidores de quinasas - Google Patents

Formas cristalinas de inhibidores de quinasas

Info

Publication number
AR083722A1
AR083722A1 ARP110101991A ARP110101991A AR083722A1 AR 083722 A1 AR083722 A1 AR 083722A1 AR P110101991 A ARP110101991 A AR P110101991A AR P110101991 A ARP110101991 A AR P110101991A AR 083722 A1 AR083722 A1 AR 083722A1
Authority
AR
Argentina
Prior art keywords
crystalline form
thieno
pyrazol
pyridin
fluorophenyl
Prior art date
Application number
ARP110101991A
Other languages
English (en)
Inventor
Geoff G Z Zhang
Paul J Brackemeyer
Ahmad Y Sheikh
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR083722A1 publication Critical patent/AR083722A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

N-(4-{4-amino-7-[1-(2-hidroxietil)-1H-pirazol-4-il]tieno[3,2-c]piridin-3-il}fenil)-N’-(3-fluorofenil)urea como base libre y formas cristalinas de la misma que son ingredientes farmacéuticos apropiados para hacer composiciones farmacéuticas útiles para el tratamiento de enfermedades, por ejemplo, cáncer. Proceso de obtención, composiciones farmacéuticas.Reivindicación 1: El compuesto N-(4-{4-amino-7-[1-(2-hidroxietil)-1H-pirazol-4-il]tieno[3,2-c]piridin-3-il}fenil)-N’-(3-fluorofenil)urea en una forma cristalina sólida, caracterizado porque la forma cristalina es la Forma I de la base libre, caracterizada por lo menos por un pico de difracción de rayos X en polvo en una o más cualesquiera de las siguientes posiciones: 7,20, 8,37, 11,38, 16,75, 16,95, 19,60, 22,04, y 22,86º 2q, ± 0,2º 2q. Reivindicación 13: El compuesto N-(4-{4-amino-7-[1-(2-hidroxietil)-1H-pirazol-4-il]tieno[3,2-c]piridin-3-il}fenil)-N’-(3-fluorofenil)urea en una forma cristalina sólida, caracterizado porque la forma cristalina es la base libre en la Forma II, caracterizada por lo menos por un pico de difracción de rayos X en polvo en una o más cualesquiera de las siguientes posiciones: 7,30, 8,81, 11,32, 15,08, 16,79, 19,46, 22,22, 22,70, 23,37, 24,29, 24,61, 25,07º 2q, ±@@@0,2º 2q.
ARP110101991A 2010-06-09 2011-06-09 Formas cristalinas de inhibidores de quinasas AR083722A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35305810P 2010-06-09 2010-06-09

Publications (1)

Publication Number Publication Date
AR083722A1 true AR083722A1 (es) 2013-03-20

Family

ID=44454740

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101991A AR083722A1 (es) 2010-06-09 2011-06-09 Formas cristalinas de inhibidores de quinasas

Country Status (18)

Country Link
US (2) US8357804B2 (es)
EP (1) EP2580219B1 (es)
JP (1) JP5711814B2 (es)
KR (1) KR20130112855A (es)
CN (1) CN103025741A (es)
AR (1) AR083722A1 (es)
AU (1) AU2011264899B2 (es)
BR (1) BR112012031469A2 (es)
CA (1) CA2802064A1 (es)
ES (1) ES2537708T3 (es)
HK (1) HK1182384A1 (es)
MX (1) MX2012014385A (es)
NZ (1) NZ605436A (es)
RU (1) RU2012157471A (es)
SG (1) SG186249A1 (es)
TW (1) TWI492949B (es)
WO (1) WO2011156461A1 (es)
ZA (1) ZA201209647B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202110406SA (en) 2019-04-11 2021-10-28 Angion Biomedica Corp Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026944A1 (en) * 2003-07-24 2005-02-03 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
GB0402518D0 (en) * 2004-02-05 2004-03-10 Astrazeneca Ab Therapeutic agents
CN101336244B (zh) * 2005-12-08 2011-11-30 雅培制药有限公司 用作蛋白激酶抑制剂的9元杂二环化合物
EP2332536A1 (en) * 2008-03-05 2011-06-15 MethylGene Inc. Inhibitors of protein tyrosine kinase activity
AU2009322270B2 (en) * 2008-12-05 2014-12-18 Abbvie Bahamas Ltd Thieno [3, 2-c] pyridine derivatives as kinase inhibitors for use in the treatment of cancer

Also Published As

Publication number Publication date
US20130136804A1 (en) 2013-05-30
BR112012031469A2 (pt) 2016-11-01
TW201204736A (en) 2012-02-01
US8357804B2 (en) 2013-01-22
ES2537708T3 (es) 2015-06-11
EP2580219B1 (en) 2015-02-25
US8592589B2 (en) 2013-11-26
KR20130112855A (ko) 2013-10-14
JP5711814B2 (ja) 2015-05-07
EP2580219A1 (en) 2013-04-17
CA2802064A1 (en) 2011-12-15
JP2013528220A (ja) 2013-07-08
AU2011264899B2 (en) 2015-01-22
ZA201209647B (en) 2014-02-26
AU2011264899A1 (en) 2013-01-10
MX2012014385A (es) 2013-05-01
SG186249A1 (en) 2013-01-30
TWI492949B (zh) 2015-07-21
HK1182384A1 (en) 2013-11-29
WO2011156461A1 (en) 2011-12-15
US20120149726A1 (en) 2012-06-14
CN103025741A (zh) 2013-04-03
RU2012157471A (ru) 2014-07-20
NZ605436A (en) 2014-11-28

Similar Documents

Publication Publication Date Title
ECSP19011216A (es) Inhibidores de piridopyrimdinona cdk2/4/6
UA108926C2 (ru) LibreOffice? [2,3-D] +" +" !+
MX2013004491A (es) Boronatos como inhibidores de arginasa.
MY162535A (en) Inhibitors of arginase and their therapeutic applications
UY33476A (es) Estimuladores de sgc
AR096758A1 (es) Inhibidores cristalinos de bromodominios
SA515360229B1 (ar) مثبطات‎ ‎عامل التمايز والنمو 8‏
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
CL2012000059A1 (es) Compuestos derivados de pirazolo[1,5-a]pirimidina; proceso de preparacion; composicion farmaceutica que los comprende; y su uso como inhbidores de trk-quinasa para el tratamiento de enfermedades o trastornos tales como dolor, cancer, inflamacion; entre otras.
BRPI0818893B8 (pt) compostos de tropano, suas composições farmacêuticas, seus usos e método in vitro de inibição de hsp90 em uma célula
CO6450612A2 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
UY31068A1 (es) Ligandos purinoreceptores p2x, metodos para la prparacion de los mismos, composiciones farmaceuticas que los contienen y sus usos 570
CR20130213A (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogènesis
CR20140216A (es) 5,7-imidazo[1,2-c]pirimidinas sustituidas
UA115320C2 (uk) Інгібітори кінази
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
CU20120171A7 (es) Triazolopiridinas sustituidas
MX2013002329A (es) Agonista de receptores de neutrofina y sus usos como medicamentos.
NI200700311A (es) Derivados de tienopirimidina y tienopiridina como inhibidores de la cinasa de flt-3
MX2012014386A (es) Formas cristalinas de inhibidores de cinasa.
BRPI0606199A2 (pt) hidrocloreto de rimonabant, processo para a preparação de um hidrocloreto de rimonabant, composição farmacêutica, forma de dosagem farmacêutica, uso de um hidrocloreto de rimonabant e método de tratamento
EA201201109A1 (ru) Прасугрель в тонкоизмельченной кристаллической форме и фармацевтическая композиция, содержащая его
UY31672A1 (es) "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación"
MX2015008187A (es) Inhibidores de alk deuterados.
EA201291014A1 (ru) Трициклическое индазольное соединение, способ его получения и содержащая его фармацевтическая композиция

Legal Events

Date Code Title Description
FB Suspension of granting procedure